Improving Outcomes of Pancreatic Cancer Surgery
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Surgical Oncology".
Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 2096
Special Issue Editors
2. Versailles St-Quentin-en-Yvelines/Paris Saclay University, UFR des Sciences de la Santé Simone Veil, Montigny-le-Bretonneux 78180, France
Interests: pancreatic surgery; liver surgery; surgical oncology; pancreatic cancer; laparoscopy; robotic
Special Issue Information
Dear Colleagues,
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers and is set to become one of the leading causes of cancer-related deaths in the next few years. Despite the advancements in surgical technique and peri-operative care in recent decades, overall survival rate for PDAC remains almost unchanged, even with the most recent chemotherapeutic regimens, mainly focused on cytotoxic drugs with or without the use of radiotherapy. From a public health point of view, surgeons can decrease the costs related to the operative procedure itself by creating a better definition of the patients who benefit from it the most and providing minimally invasive surgery when suitable.
On the other hand, the advent of early diagnosis with the potential use of liquid biopsy and the use of immunotherapy are still in their infancies, and a lot must be done in this field. The use of immunotherapy as an adjuvant treatment for surgery is still evolving, with some encouraging results emerging. Minimally invasive techniques (laparoscopic and robotic) have become the standard of practice for most distal body and tail lesions; however, in randomized trials, the routine use of such techniques in cephalic resections has not shown its superiority to the open approach. More recently, metastatic disease, once considered to be an absolute contraindication for surgery, has begun to be treated, with promising results.
This Special Issue aims to offer an update on the cutting-edge treatment of PDAC and contribute to the current medical literature on this topic. Herein, we are pleased to invite you to join us in this Special Issue of Current Oncology by submitting either your basic, translational or clinical studies.
We look forward to receiving your contributions.
Dr. Renato M. Lupinacci
Prof. Dr. Marcos Perini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic ductal adenocarcinoma
- prognosis
- survival
- chemotherapy
- recurrence
- surgery
- pancreas cancer
- pancreatectomy
- pancreatic resections
- robotic
